You are here:
Hepatitis
#

Hepatitis

Get Alerts

Articles

View all

Chemist gets a taste of his own medicine!

Feb 10, 2014

Chemist gets a taste of his own medicine!

Bharti AXA has launched the Smart Health Critical Illness Insurance policy that offers lump sum compensation that helps meet day-to-day expenses and cover hospitalization costs. #Stroke #compensation #prescription #cardiovascular disease #Kidney failure #chemist #Bharti AXA #Smart Health Critical Illness Insurance Plan #Daily Expenses #Fulminant Hepatitis #Hospitalisation Cost #Working Patient #Digital Campaign
IndioLabs cuts down biopsy time to 3 seconds with new device

Dec 17, 2013

IndioLabs cuts down biopsy time to 3 seconds with new device

BioScoop extracts tissue automatically, eliminating the possibility of contamination and other problems associated with conventional biopsy, all in three seconds. #NewsTracker #Hepatitis #Liver #biopsy #BioScoop #IndioLabs
114 kids in WB hospital after getting Hepatitis B vaccine instead of polio

Sep 16, 2013

114 kids in WB hospital after getting Hepatitis B vaccine instead of polio

Hepatitis B is administered through injection while pulse polio drops are given orally. #India #NewsTracker #West Bengal #Polio vaccine #Vaccine #hospital #Hepatitis B vaccine
Peg or two lowers risk of liver disease

Apr 23, 2012

Peg or two lowers risk of liver disease

People with non-alcoholic fatty liver disease (NALFD), who consume alcohol in modest quantity, on a daily basis are half as likely to develop hepatitis as non-alcoholics with the same condition, says a new study. #didyouknow #Cirrhosis #Liver disease #Hepatitis #Fatty liver #Hepatocellular carcinoma

Wire

View all

Peg or two lowers risk of liver disease

Jul 21, 2014

'True Blood' recap: Bon Temps celebrates life as body count grows

It’s hard to imagine a more challenging time in Bon Temps as the town struggles to recover from vampire attacks, vigilantism and the deadly hepatitis V virus...
Peg or two lowers risk of liver disease

Jul 20, 2014

Lucrative Drug Niche Sparks Legal Scramble

The pharmaceutical industry's battle for dominance in the fast-growing and lucrative market for treatments of hepatitis C is prompting an unprecedented legal scramble...
Peg or two lowers risk of liver disease

Jul 11, 2014

U.S. senators ask Gilead Sciences to explain high cost of hepatitis C drug

Two U.S. senators asked Gilead Sciences Inc. to produce documents explaining why its new hepatitis C drug is priced at $84,000 per treatment course, raising renewed concerns over the high costs to taxpayers...